文献速递血液净化与透析

基于云的人工智能应用对血液透析动静脉血管通路动脉瘤的分类:一项掩蔽多中心衍生队列研究的结果

Cloud-Based AI Application for Classifying Arteriovenous Hemodialysis Vascular Access Aneurysms: Findings from a Masked Multicenter Derivation Cohort Study.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-10-01

本研究在2个血管通路中心、覆盖21个透析诊所的120例中心血液透析患者中,采集720张动静脉通路图像,比较云端动脉瘤分类应用(ACA)与专科医生现场评估的分类性能。以医生分类为金标准,ACA的AUROC为0.908(95%CI 0.843-0.963),在最大约登指数下敏感度96%、特异度82%。结论认为ACA在此次掩蔽评估中准确性较好,但需更大规模独立队列及真实世界条件验证。

要点

  • ACA对动静脉通路动脉瘤分类的AUROC为0.908,敏感度96%、特异度82%。
  • 医生判定22%患者为进展期动脉瘤,ACA在最大约登指数下判定35%为进展期。
  • 结论需在更大独立队列和真实世界条件下进一步验证后方可推广。

核心结论

  • ACA在此次初始掩蔽评估中显示出较好的动脉瘤分类准确性,但更广泛临床部署前需进一步验证。

研究设计与样本

  • 单掩蔽、多中心、观察性横断面研究,在2个血管通路中心(覆盖21个血液透析诊所)进行。
  • 纳入120例中心血液透析患者,采集720张动静脉通路图像(每人6张),以医生分类为金标准分析ACA性能。

主要发现

  • 患者平均年龄62岁,66例为男性。
  • 医生分类26例(22%)为进展期动脉瘤,94例(78%)为非进展期。
  • ACA的AUROC为0.908(95%CI 0.843-0.963)。
  • 在最大约登指数下,ACA分类42例(35%)为进展期、78例(65%)为非进展期,敏感度96%、特异度82%。

临床怎么用

  • ACA可作为基于移动设备图像的辅助工具,帮助早期识别进展期动静脉通路动脉瘤。
  • 当前证据支持在进一步验证前将ACA用于研究或辅助评估场景,而非替代医生现场评估。

局限性

  • 作者指出需在更大、独立队列及真实世界条件下进一步验证。
  • 本研究为初始掩蔽评估,样本来自特定中心与诊所网络。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In hemodialysis patients, arteriovenous fistulas (AVF) are the preferred vascular access for most hemodialysis patients. However, aneurysms of the AVF can lead to severe complications, including rupture and life-threatening exsanguination. To address this risk, we recently developed, trained, and validated a convolutional neural network capable of classifying digital images of arteriovenous aneurysms captured via mobile devices as showing either "Advanced" or "Not Advanced" aneurysms. This cloud-based aneurysm classification application (ACA) aims to facilitate early detection of advanced aneurysms, potentially reducing morbidity and improving outcomes. Our study aimed to compare the diagnostic performance of ACA with in-person aneurysm assessments by physicians specialized in vascular access care. METHODS: We conducted a single-masked, multicenter, observational, cross-sectional study at two vascular care centers with a catchment area of 21 hemodialysis clinics. Using mobile devices, research staff captured images of arteriovenous accesses and uploaded them to the cloud. The ACA then computed the probability of "Advanced" and "Not Advanced" aneurysms. Separately, physicians masked to the ACA results performed thorough physical and ultrasound examinations of the AVF and classified aneurysms as "Advanced" or "Not Advanced". Physician classifications served as the ground truth for ACA performance analysis. RESULTS: We analyzed 720 images from 120 incenter hemodialysis patients (six images per patient). Mean patient age was 62 years, 66 were male. Physicians classified 26 patients (22%) having "Advanced" aneurysms and 94 (78%) having "Not Advanced" aneurysms. The ACA achieved an AUROC of 0.908 (95% confidence interval: 0.843-0.963). At the maximum Youden index, ACA classified 42 aneurysms (35%) as "Advanced" and 78 (65%) as "Not Advanced," yielding a sensitivity of 96% and a specificity of 82%. CONCLUSION: The ACA demonstrated promising accuracy in this initial masked evaluation. Further validation in larger, independent cohorts and under real-world conditions is warranted before broader clinical deployment.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Dong Z, Zhang H, Wang LC, et al. Cloud-Based AI Application for Classifying Arteriovenous Hemodialysis Vascular Access Aneurysms: Findings from a Masked Multicenter Derivation Cohort Study. Clin J Am Soc Nephrol. 2026. PMID: 42821327. doi:10.2215/CJN.0000001231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。